Background: Low-dose psilocybin is increasingly promoted as a practical route to improved mood, emotional balance, and general mental wellness. Public claims frequently merge three pharmacologically different exposures: mushroom or truffle microdoses intended to be minimally perceptible, purified psilocybin doses of 5–10 mg, and 20–25 mg regimens that reliably produce an overt psychedelic experience. That merger obscures what has actually been tested.
Objective: To critically evaluate human evidence for the effectiveness or efficacy of low-dose psilocybin on well-being, anxiety, depression, stress, and disorder-specific psychiatric outcomes.
Methods: A targeted narrative review was conducted using PubMed, publisher platforms, preprint servers, and reference-list tracing through 17 July 2026. Human studies of psilocybin-containing mushrooms or truffles described as microdoses, and purified or standardized psilocybin doses at or below 10 mg, were included when they reported mental-health or well-being outcomes. Studies above 10 mg were used only to define the dose boundary and prevent inappropriate extrapolation.
Results: Large observational cohorts and prospective naturalistic studies repeatedly associate microdosing with modest improvements in mood or psychological distress. These studies cannot estimate a drug-specific causal effect because exposure is self-selected, dosing is often chemically unverified, expectancy is high, and outcomes are largely self-reported. In psilocybin-specific blinded studies using approximately 0.9–1.5 mg, detectable subjective or electrophysiologic effects did not translate into reliable improvements in depression, anxiety, emotional processing, cognition, or well-being beyond placebo. Two controlled longitudinal trials published in 2026 likewise found no robust emotional or cognitive benefit. A 2026 preprint in mild-to-moderate major depressive disorder found nearly identical PHQ-9 improvement after a nominal 2-mg product and placebo. At 5–10 mg, small obsessive-compulsive disorder studies provide a disorder-specific hypothesis signal; depression trials have not established efficacy at these doses.
Conclusions: Current evidence does not establish low-dose psilocybin as an effective intervention for broad mental wellness or depressive symptoms. The literature contains an observational signal, a substantial expectancy signal, and a limited OCD signal. These are scientifically distinct. Future trials require chemically verified dosing, symptomatic populations, credible active controls, explicit measurement of blinding and expectancy, multiplicity control, and independent replication.
Keywords: psilocybin; microdosing; low dose; mental wellness; depression; anxiety; placebo; expectancy; obsessive-compulsive disorder; efficacy.
Introduction
Microdosing has achieved cultural certainty faster than clinical certainty. The practice is typically described as repeated ingestion of a small amount of a psychedelic—often 0.1–0.5 g of dried psilocybin-containing mushrooms or an estimated 1–2 mg of psilocybin—at a level intended to preserve ordinary functioning. The desired outcomes are diffuse but attractive: improved mood, less anxiety, greater emotional stability, enhanced creativity, and a general sense of psychological well-being. These claims now circulate beside clinical findings from 20–25 mg psilocybin sessions, creating the impression of a single, continuous evidence base. It is not one evidence base.
A pharmacologic intervention must be judged at the dose, schedule, population, comparator, and endpoint actually studied. A 25-mg session that produces a sustained psychedelic experience cannot validate a 1-mg regimen designed to avoid one. Likewise, a transient reduction in compulsions in a small obsessive-compulsive disorder (OCD) sample cannot be converted into proof of generalized mental wellness. The relevant question is narrower: when low-dose psilocybin is separated from full-dose psychedelic therapy and tested against an adequate control, does it improve mental-health outcomes?
The answer matters because the term “microdosing” has become a rhetorical shortcut. It can refer to an imprecise weight of fungal material, a chemically measured quantity of psilocybin, a subthreshold subjective state, or simply a dose lower than those used in conventional psychedelic therapy. These definitions are not interchangeable. This review therefore treats dose classification as part of causal inference rather than as background terminology.
Scope and approach
This mini-review is a critical narrative synthesis, not a systematic review or meta-analysis. Searches of PubMed, journal platforms, preprint servers, and reference lists were updated through 17 July 2026 using combinations of psilocybin, microdose, low dose, well-being, mood, anxiety, depression, stress, OCD, randomized, placebo, blinded, and trial. Eligible evidence included human studies of psilocybin-containing mushrooms or truffles described as microdoses and human studies of purified or standardized psilocybin at doses of 10 mg or less that reported psychological, psychiatric, or well-being outcomes. Mixed-psychedelic studies were retained only when they informed expectancy, self-selection, or general microdosing methodology. Studies above 10 mg were excluded from the efficacy synthesis and cited only when they exposed dose-dependent interpretation.
The review distinguishes effectiveness signals from efficacy estimates. Effectiveness refers here to outcomes observed in naturalistic use, where participants choose whether, what, and how to dose. Efficacy requires a controlled comparison capable of isolating the contribution of the drug from expectancy, trial participation, concurrent behavior, regression to the mean, and other influences. Both forms of evidence have value, but they answer different questions.
The dose-definition problem
The first threat to valid interpretation is dose-category substitution: evidence generated at one exposure level is used to support claims at another. The error is common because the independent variable is often described by a cultural label rather than by verified drug content. Dried mushroom weight is an unstable proxy for psilocybin exposure. Species, strain, cultivation, storage, cap-to-stem ratio, and product homogeneity can all alter alkaloid content. “One-tenth of a recreational dose” is equally unstable because the reference dose varies across people and products.
Table 1. Dose categories used in this review. The boundaries are operational, because no universal pharmacologic definition of a microdose exists. NOT MEDICAL ADVICE.
Dose labels also conceal a second distinction: pharmacologic activity is not equivalent to clinical benefit. A dose can be measurable in plasma, alter electroencephalographic activity, or produce a subtle subjective effect while failing to improve mood or functioning. The microdosing hypothesis requires evidence at the level of patient-centered outcomes, not merely evidence that the brain noticed the drug.
WE OFFER A COURSE ON NEUROHEALTH AT IPAKEDU.ONLINE – LEARN ABOUT WHAT MAKES AND KEEPS A BRAIN HEALTHY WITH DR. JACK AND COLLEAGUES! 30% DISCOUNT ON ALL COURSES FOR MEMBERS OF IPAKEDU.ONLINE
Observational studies: a reproducible signal but no causal estimate
The strongest positive case for psilocybin microdosing comes from observational research. In a 2022 prospective cohort, 953 psilocybin microdosers were compared with 180 non-microdosing participants over approximately one month. Microdosers showed small-to-moderate improvements in mood and mental-health measures, including among older adults [2]. A related cross-sectional analysis of more than 8,700 respondents reported lower depression, anxiety, and stress among microdosers than non-microdosers; approximately 85% of microdosers reported psilocybin as the substance used [3]. The between-group standardized differences were small, approximately 0.12–0.19, but directionally consistent.
Prospective naturalistic work has produced a similar pattern. Kaertner and colleagues observed increases in psychological well-being and reductions in depression and anxiety across four weeks of self-initiated microdosing [4]. Polito and Stevenson reported improved mood, attention, and selected mental-health measures during a naturalistic monitoring period, alongside less uniformly favorable findings such as increased neuroticism [5]. Surveys of self-treatment also find that users frequently perceive microdosing as helpful for anxiety, depression, substance use, and other problems [6,7].
These findings should not be dismissed. A signal that recurs across large samples can identify outcomes worth testing, plausible subgroups, and patterns of use that laboratory studies might miss. The inferential ceiling, however, is low. Participants self-select into exposure; many have prior psychedelic experience; recruitment often occurs in communities already favorable toward psychedelics; products and schedules vary; “stacking” with lion’s mane, niacin, cannabis, or other substances is common; and outcomes are usually self-reported. In the Kaertner study, baseline positive expectancy predicted subsequent improvement [4]. That is not a nuisance variable. It is a direct warning that the observed trajectory may partly measure belief.
Competing-interest context also deserves visibility. The large Microdose.me publications disclosed relationships with the data-collection platform, commercial psychedelic organizations, and intellectual property concerning microdosing combinations [2,3]. Disclosure does not invalidate results, but it raises the importance of independent replication and restrained causal language. The appropriate conclusion from this literature is that people who choose to microdose often report feeling better. It does not establish that low-dose psilocybin caused the improvement.
Placebo-controlled microdosing: the signal repeatedly contracts
When psilocybin microdosing is examined under blinded conditions, the claimed wellness effect becomes difficult to locate. Marschall and colleagues used a preregistered, double-blind, placebo-controlled crossover design with 0.7 g of dried truffles, estimated at approximately 1.5 mg psilocybin [8]. Confirmatory analyses found no effect on depression, anxiety, emotional processing, or related symptom measures compared with placebo. Both placebo and psilocybin periods improved from baseline, a pattern compatible with expectancy, enrollment effects, or repeated measurement. The sample was generally healthy, so floor effects limit generalization to symptomatic patients. Even so, the study does not support broad wellness efficacy.
Cavanna and colleagues administered 0.5 g of dried Psilocybe cubensis, chemically estimated to contain roughly 0.9 mg psilocybin, in a double-blind placebo-controlled study [9]. Participants experienced detectable subjective and electroencephalographic changes. They did not show improved well-being, creativity, cognition, mental-health measures, or physical activity. The dissociation is important: biologic activity was present without demonstrated clinical benefit. Participants correctly identified a substantial proportion of active sessions, and apparent subjective advantages concentrated among those who recognized the condition, again placing functional unblinding near the center of interpretation.
Two double-blind longitudinal trials reported in 2026 provide the most direct recent test of repeated psilocybin microdosing in healthy participants [10]. Across cognitive, emotional, mood, and well-being measures, the investigators found no reliable improvement beyond placebo. Initial positive signals did not survive correction for multiple comparisons, while some negative bodily sensations increased. These trials reduce the plausibility that failure in earlier work was merely a consequence of one laboratory, one schedule, or one endpoint.
The best-known self-blinding citizen-science study involved both psilocybin and lysergic acid diethylamide and therefore cannot provide a psilocybin-specific estimate [11]. It remains methodologically instructive: outcomes improved from baseline in the microdose group, yet placebo participants improved similarly, and differences were largely explained by participants’ guesses about what they had taken. A related psilocybin study reported greater awe in response to selected stimuli [12], but the paper arose from the same broader participant project as the Marschall study and should not be counted as independent replication. Moreover, increased awe toward funny animals or moving objects is not equivalent to improved global mental wellness.
The first controlled patient study squarely targeting microdosing and depression further sharpens the picture. A 2026 Research Square preprint randomized 39 adults with mild-to-moderate major depressive disorder to four weekly doses of a nominal 2-mg product or placebo, followed by open-label dosing [13]. The methods describe the product as 2 mg of Psilocybe cubensis extract equivalent to 1 mg psilocybin, an internal dose-reporting ambiguity that should be corrected in peer review. At four weeks, PHQ-9 scores declined by 5.4 points in the active group and 6.0 points in the placebo group. No statistically greater antidepressant efficacy was demonstrated. The improvement was real; the drug-specific advantage was absent.
Five to ten milligrams: a different exposure and a different claim
Doses of 5–10 mg should not be described as microdoses by default. They are usually perceptible, may require clinical monitoring, and can engage mechanisms linked to the acute psychedelic state. Their evidence must be considered separately.
The most encouraging low-clinical-dose findings concern OCD. In a 2025 pharmacologic challenge study, 19 adults entered a fixed-order protocol involving 1 mg followed four weeks later by 10 mg; 18 completed the study [14]. One week after 10 mg, total Yale–Brown Obsessive Compulsive Scale scores fell with a reported effect size of d=0.82, driven mainly by compulsions. Depressive symptoms did not improve. The signal is clinically interesting, yet the fixed order, absence of a randomized concurrent placebo group, small sample, and short follow-up prevent a causal efficacy conclusion.
A 2026 randomized OCD trial assigned 15 participants—five per group—to four weekly sessions of 100 μg/kg psilocybin, 300 μg/kg psilocybin, or lorazepam active placebo, followed by four weekly high-dose sessions for all groups [15]. During the randomized phase, low-dose participants had lower average next-day OCD scores than placebo when values were collapsed across time. However, the low-dose within-group slope was not significant (p=0.21), and the condition-by-time interaction was not significant. One-week effects likewise showed no significant condition-by-time interaction. Response and remission rates reported after eight weeks cannot isolate the low dose because nearly all participants had then received at least four high doses. With n=5 per condition, the study is a feasibility-level signal, not a stable estimate of low-dose efficacy.
Depression trials provide a useful counterweight. In a large randomized study of treatment-resistant depression, 25 mg produced a significantly greater reduction in symptoms than 1 mg, while 10 mg did not [16]. The result supports dose dependence and directly undermines the practice of attributing the 25-mg effect to lower exposures. More recently, the 144-participant EPISODE trial found no statistically significant week-six advantage for 25 mg over active placebo and no evidence of efficacy for the 5-mg group [17]. The overall psilocybin-depression literature remains active and heterogeneous, but these data do not support 5–10 mg as an established antidepressant regimen.
Healthy-volunteer dose-ranging studies are sometimes cited as evidence for wellness. Griffiths and colleagues showed that 5 mg/70 kg could produce detectable acute effects, while the strongest enduring positive ratings occurred after 20 or 30 mg/70 kg [18]. A phase 1 study found that 10 and 25 mg were generally tolerated without persistent cognitive or emotional impairment [19]. These are valuable safety and phenomenology findings. They do not demonstrate efficacy for low-dose mental wellness.
Table 2. Principal human studies informing low-dose psilocybin claims. Mixed-psychedelic studies are omitted except where directly relevant to expectancy.
Why the observational and controlled literatures diverge
Expectancy and functional unblinding
Microdosing trials face an unusual paradox: the intervention is defined as subtle, yet participants are often highly motivated to detect it. Small changes in bodily sensation, attention, or arousal can reveal allocation. Once a participant believes the active drug was received, subsequent self-ratings can incorporate hope, confirmation, and post hoc interpretation. An inert placebo does not neutralize this process if the active dose is recognizable. Trials should therefore report blinding indices at each session, model guessed assignment, and consider active controls that reproduce nonspecific sensations without approximating the psychedelic mechanism.
Endpoint abundance and analytic flexibility
Microdosing studies often measure mood, well-being, creativity, attention, emotion recognition, mindfulness, personality, and bodily sensations simultaneously. This breadth is understandable in an exploratory field, but it creates a large search space for chance findings. The 2026 controlled trials are instructive because apparent signals disappeared after multiplicity correction [10]. Future confirmatory studies should specify one primary clinical endpoint, a clinically meaningful time point, and a hierarchical testing plan before unblinding.
Population mismatch
Healthy participants can answer whether low-dose psilocybin enhances functioning above an already normal baseline. They are poorly suited to estimate antidepressant effects when depression scores begin near the floor. Patient trials solve that problem but introduce others: heterogeneity in illness duration, prior treatment, concurrent psychotherapy, medication washout, and regression to the mean. “Mental wellness” should therefore be decomposed into prevention or enhancement in healthy people, symptom reduction in subclinical distress, and treatment of a diagnosed disorder. Evidence in one category does not automatically transfer to another.
Product uncertainty and regimen heterogeneity
Fungal material is a variable drug-delivery system. A nominal mushroom weight cannot guarantee psilocybin content, and a branded extract may still be described inconsistently, as illustrated by the 2026 depression preprint [13]. Schedules also vary from intermittent self-dosing to weekly supervised administration. Reproducibility requires verified alkaloid content, batch testing, pharmacokinetic sampling in a subset, and full reporting of co-administered substances and behavioral interventions.
Paper count is not replication count
A field can appear larger than it is when several publications arise from one participant project, when the same commercial cohort generates multiple analyses, or when mixed-substance studies are summarized as psilocybin evidence. Evidence maps should identify overlapping samples and distinguish psilocybin-specific trials from studies that pool LSD, mushrooms, and other psychedelics. Without that accounting, the apparent consistency of the literature is inflated.
What the evidence supports—and what it does not
The current literature supports five propositions. First, low doses of psilocybin can be pharmacologically and subjectively detectable. Second, many people who self-select into microdosing report improvements in mood or distress. Third, expectancy predicts part of that improvement and can generate changes resembling a treatment response. Fourth, placebo-controlled psilocybin microdosing studies have not demonstrated a reliable benefit for broad well-being, anxiety, depression, emotional processing, or cognition. Fifth, 5–10 mg dosing warrants continued study for selected disorders, particularly OCD, but the evidence remains too small and design-limited for generalized claims.
The literature does not support marketing low-dose psilocybin as an established treatment for mental wellness, depression, or anxiety. It does not justify equating self-reported naturalistic improvement with pharmacologic efficacy. It does not justify importing outcomes from 20–25 mg assisted-therapy trials into microdosing claims. It does not establish the long-term safety of repeated use across heterogeneous, unscreened populations. A null efficacy conclusion at present is not a declaration that benefit is impossible. It is a statement that benefit has not been isolated from placebo and context with sufficient reliability.
Research priorities
• Studies that recruit participants with prespecified, clinically meaningful baseline symptoms rather than relying exclusively on healthy convenience samples.
• Studies that ese chemically verified psilocybin content and report the dose of active alkaloid separately from extract or fungal-material weight.
• Studies that employ credible active controls, measure guessed allocation after every dose, and prespecify how unblinding will be incorporated into sensitivity analyses. Alternative: BABA design studies.
• Studies that choose one primary patient-centered endpoint and one primary time point; control multiplicity for secondary outcomes.
• Studies that stratify expectancy, prior psychedelic exposure, concomitant medication, psychotherapy, and substance use before randomization.
• Studies that extend repeated-dose safety observation beyond four to eight weeks and report adverse events by dose session, not merely by participant.
• Independent replication before a disorder-specific signal is translated into a broad wellness claim.
Conclusion
Low-dose psilocybin occupies an evidentiary gap between compelling personal testimony and as-yet unconfirmed clinical efficacy. Observational studies repeatedly identify a modest mental-health signal, but the signal contracts under placebo control. The most recent patient-level evidence shows the same phenomenon: depressive symptoms can improve substantially during a microdosing trial while improving no more with the active product than with placebo. That is a finding about context and expectancy as much as it is a finding about psilocybin.
The scientifically defensible position is neither enthusiasm nor dismissal. Microdosing remains a plausible hypothesis with in search of efficacy support. Low clinical doses of 5–10 mg remain a separate hypothesis, with preliminary OCD findings and negative or inconclusive depression evidence. The field will advance when it stops treating every low exposure as the same intervention and every improvement as a drug effect. Dose integrity, comparator credibility, endpoint discipline, and independent replication are the requirements for converting a cultural practice into a clinically interpretable treatment.
Combined therapy studies with lifestyle changes, ketogenic diet and non-pharmacological therapies and counseling are in order.
References
1. Polito V, Liknaitzky P. The emerging science of microdosing: A systematic review of research on low dose psychedelics (1955–2021) and recommendations for the field. Neurosci Biobehav Rev. 2022;139:104706. doi:10.1016/j.neubiorev.2022.104706. PMID:35609684
2. Rootman JM, Kiraga M, Kryskow P, et al. Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls. Sci Rep. 2022;12:11091. doi:10.1038/s41598-022-14512-3. PMID:35773270. A published correction is available at doi:10.1038/s41598-022-17428-0
3. Rootman JM, Kryskow P, Harvey K, et al. Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers. Sci Rep. 2021;11:22479. doi:10.1038/s41598-021-01811-4. PMID:34795334
4. Kaertner LS, Steinborn MB, Kettner H, et al. Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing. Sci Rep. 2021;11:1941. doi:10.1038/s41598-021-81446-7. PMID:33479342
5. Polito V, Stevenson RJ. A systematic study of microdosing psychedelics. PLoS One. 2019;14:e0211023. doi:10.1371/journal.pone.0211023. PMID:30726251
6. Lea T, Amada N, Jungaberle H, Schecke H, Scherbaum N, Klein M. Perceived outcomes of psychedelic microdosing as self-managed therapies for mental and substance use disorders. Psychopharmacology (Berl). 2020;237:1521–1532. doi:10.1007/s00213-020-05477-0. PMID:32043165
7. Hutten NRPW, Mason NL, Dolder PC, Kuypers KPC. Self-rated effectiveness of microdosing with psychedelics for mental and physical health problems among microdosers. Front Psychiatry. 2019;10:672. doi:10.3389/fpsyt.2019.00672. PMID:31572246
8. Marschall J, Fejer G, Lempe P, Prochazkova L, Kuchar M, Hajkova K, van Elk M. Psilocybin microdosing does not affect emotion-related symptoms and processing: A preregistered field and lab-based study. J Psychopharmacol. 2022;36:97–113. doi:10.1177/02698811211050556. PMID:34915762
9. Cavanna F, Muller S, de la Fuente LA, et al. Microdosing with psilocybin mushrooms: A double-blind placebo-controlled study. Transl Psychiatry. 2022;12:307. doi:10.1038/s41398-022-02039-0. PMID:35918311
10. Prochazkova L, van Elk M, Marschall J, et al. Cognitive and subjective effects of psilocybin microdosing: Results from two double-blind placebo-controlled longitudinal trials. Neuropharmacology. 2026;283:110722. doi:10.1016/j.neuropharm.2025.110722. PMID:41110634
11. Szigeti B, Kartner L, Blemings A, et al. Self-blinding citizen science to explore psychedelic microdosing. eLife. 2021;10:e62878. doi:10.7554/eLife.62878. PMID:33648632
12. van Elk M, Fejer G, Lempe P, Prochazkova L, Kuchar M, Hajkova K, Marschall J. Effects of psilocybin microdosing on awe and aesthetic experiences: A preregistered field and lab-based study. Psychopharmacology (Berl). 2022;239:1705–1720. doi:10.1007/s00213-021-05857-0. PMID:33928421
13. Petranker R, Farb N, Syed O, et al. Safety and efficacy of microdosing psilocybin over 8 weeks for major depressive disorder: A randomized clinical trial. Research Square [preprint]. Version 1; posted 2026. doi:10.21203/rs.3.rs-8319478/v1. Not peer reviewed
14. Pellegrini L, Fineberg NA, O’Connor S, et al. Single-dose (10 mg) psilocybin reduces symptoms in adults with obsessive-compulsive disorder: A pharmacological challenge study. Compr Psychiatry. 2025;142:152619. doi:10.1016/j.comppsych.2025.152619. PMID:40618640
15. Moreno FA, Allen KE, Wiegand CB, et al. A randomized clinical trial of repeated doses of psilocybin for the treatment of obsessive-compulsive disorder. J Psychopharmacol. 2026;40:837–849. doi:10.1177/02698811261424214. PMID:41825921
16. Goodwin GM, Aaronson ST, Alvarez O, et al. Single-dose psilocybin for a treatment-resistant episode of major depression. N Engl J Med. 2022;387:1637–1648. doi:10.1056/NEJMoa2206443. PMID:36322843
17. Mertens LJ, Koslowski M, Betzler F, et al. Efficacy and safety of psilocybin in treatment-resistant major depression: The EPISODE randomized clinical trial. JAMA Psychiatry. 2026;83:448–460. doi:10.1001/jamapsychiatry.2026.0132. PMID:41848690
18. Griffiths RR, Johnson MW, Richards WA, Richards BD, McCann U, Jesse R. Psilocybin occasioned mystical-type experiences: Immediate and persisting dose-related effects. Psychopharmacology (Berl). 2011;218:649–665. doi:10.1007/s00213-011-2358-5. PMID:21674151
19. Rucker JJH, Marwood L, Ajantaival RLJ, et al. The effects of psilocybin on cognitive and emotional functions in healthy participants: Results from a phase 1 randomized placebo-controlled trial involving simultaneous psilocybin administration and preparation. J Psychopharmacol. 2022;36:114–125. doi:10.1177/02698811211064720. PMID:35090363
20. Ona G, Bouso JC. Potential safety, benefits, and influence of the placebo effect in microdosing psychedelic drugs: A systematic review. Neurosci Biobehav Rev. 2020;119:194–203. doi:10.1016/j.neubiorev.2020.09.035. PMID:33031815
21. Kuypers KPC. The therapeutic potential of microdosing psychedelics in depression. Ther Adv Psychopharmacol. 2020;10:2045125320950567. doi:10.1177/2045125320950567. PMID:32922736
22. Lo DF, Sengupta S, Mead A, Lea T, Lee C, Lawrence AJ. Modern psychedelic microdosing research on mental health: A systematic review. Prim Care Companion CNS Disord. 2024;26:23r03581. doi:10.4088/PCC.23r03581. PMID:38228068
23. Totomanova I, Figueiredo IM, Morgan CJA. A critical review of psychedelic microdosing. Curr Opin Psychol. 2025;65:102129. doi:10.1016/j.copsyc.2025.102129. PMID:40834796
IPAK-EDU is grateful to Popular Rationalism as this piece was originally published there and is included in this news feed with mutual agreement. Read More
Leave a Reply